Drug Profile


Alternative Names: BM 211290; Fozivudine tidoxil; FZT; HDP 99.0002; HDP 990002; W 09726867

Latest Information Update: 29 Jan 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Heidelberg Pharma
  • Class Antivirals; Deoxyribonucleosides; Dideoxynucleosides; Lipids; Pyrimidine nucleosides
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 18 May 2005 Fozivudine is available for licensing (
  • 15 Jun 2004 Phase-II clinical trials in HIV infections treatment in Germany (PO)
  • 10 Jul 2000 A phase II study has been added to the adverse events, pharmacokinetics and Viral infections therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top